Novartis Approves Sandoz's New Board Ahead of Spinoff
15 Maio 2023 - 03:08AM
Dow Jones News
By Giulia Petroni
Novartis said Monday that its generics unit Sandoz has appointed
a new board of directors ahead of the planned spinoff and listing
on the Swiss stock exchange.
The Swiss pharma major said Sandoz's board will count 10 members
and three sub-committees, namely innovation and development, human
capital and ESG, and audit, risk and compliance. It will be
effective after the spinoff in the second half of the year.
Among its members, the board will have former chief executive
officer of Solvias Group, Karen Huebscher; former CEO of Emmi
Group, Urs Riedener; and CEO of Nestle, Francois-Xavier Roger, as
chairs of the sub-committees.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
May 15, 2023 01:53 ET (05:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024